The latest update is out from Onconetix ( (ONCO) ).
On March 19, 2025, Onconetix announced that its abstract on the clinical performance of Proclarix, a prostate cancer diagnostic test, was accepted for presentation at the 2025 European Association of Urology congress in Madrid. The presentation will highlight Proclarix’s ability to reduce unnecessary biopsies by effectively ruling out clinically insignificant prostate cancer, demonstrating its potential impact on improving prostate cancer diagnosis and treatment.
More about Onconetix
Onconetix, Inc. is a commercial stage biotechnology company focused on men’s health and oncology. The company specializes in the research, development, and commercialization of innovative solutions, including Proclarix, an in vitro diagnostic test for prostate cancer, and ENTADFI, a treatment for benign prostatic hyperplasia.
YTD Price Performance: -80.92%
Average Trading Volume: 10,166,483
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.81M
Find detailed analytics on ONCO stock on TipRanks’ Stock Analysis page.